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Abstract
Background: Microtubule-associated protein tau (MAPT) is a neuronal protein involved in the pathogenesis of
several neurodegenerative diseases including Parkinson’s Disease (PD). Glycogen synthase kinase 3 beta (GSK3B)
catalyzes phosphorylation in multiple sites of tau protein. However, whether or not there is any association
between the GSK3B gene alteration, MAPT haplotype and PD remains unexplored in Chinese population, especially
in central Chinese population.
Results: Here, we aimed at studying the effect of MAPT rs242562 and GSK3B rs334558 on the risk of PD by performing
a case-control association study in central China. Our data showed that all PD patients and controls were of MAPT H1/
H1 diplotype in our study, thus confirming that the distribution of the MAPT H1 haplotype is common in China. GG
genotype of MAPT rs242562 serves protection effect on PD risk in central Chinese population, while genotype of GSK3B
rs334558 showed no difference between PD patients and controls.
Conclusions: We conclude that the MAPT rs242562 is associated with PD in central China in the background of MAPT
H1/H1 diplotype. The GG genotype of rs242562 displays protection against PD in subgroup with GSK3B rs334558 T carrier.
Keywords: MAPT H1 haplotype, GSK3β,P a r k i n s o n ’s disease, Genetic risk factor
Background
Parkinson’s disease (PD) is a common neurodegenerative
disease in elders, characterized by the loss of dopamin-
ergic neurons in substantial nigra and the formation of
Lewy bodies [1]. PD affects approximately 1% of popula-
tion aging over 60 years. Disease onset before 50 years
of age defines as early-onset Parkinson's disease (EOPD)
while that over 50 years of age, as late onset Parkinson’s
disease (LOPD). The etiology and pathogenesis of PD,
mainly considered to be related with aging, genetic
and environmental factors, is incompletely understood.
Recently, linkage analysis and genomewide association
studies have shown that PARK1-PARK18, POLG, Glycogen
Synthase kinase-3B (GSK3B), Microtubule-associated protein
tau (MAPT) and other genes are associated with PD risk.
The MAPTgene is localized in a region of extended link-
age disequilibrium (LD) on chromosome 17q21, containing
16 exons and encoding microtubule-associated proteins
tau. Tau proteins, constituting a family of six isoforms
ranging between 352-441 amino acids, are widely expressed
in the nervous system. Excessive phosphorylation of tau
proteins leads to abnormal intracellular aggregation,
formatting of the double helix fiber filament, producing
the nerve fiber tangles, and finally neurodegeneration
[2]. MAPT gene, defines two extended haplotype, H1 and
H2. The determination of MAPT haplotype H1/H2 is
attributed to the presence of a 238 bp deletion between
exons 9 and 10 of MAPT H2 haplotype [3]. H1 haplotype
is reportedly related to PD susceptibility [4]. Concerning
sub-haplotypes, there is a positive correlation between
MAPT H1 haplotype and PD, including SNP rs242562
(A/G) and rs2435207 (G/A). The A-A sub-haplotype is
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while the G-A sub-haplotype for these two SNPs is
associated with PD subjects in Greece [5-7]. However,
at present, little is known about the correlation between
MAPT gene polymorphism and PD patients in China,
especially in central China area. Central China includes
six widely agricultural provinces namely Hunan, Hubei,
Jiangxi, Henan, Shanxi and Anhui.
GSK3B protein is widely expressed in all tissues, with
particularly abundant levels in the brain [8]. The funda-
mental role of GSK3B in intracellular neuronal signaling
systems is underpinned by its ability to phosphorylate
several proteins that contribute to the structural charac-
teristics and dynamics of neuronal cells. In addition, it
has been proven that GSK3B catalyzes phosphorylation
in multiple sites of tau protein [9], and it is an important
pathogenic protein kinase for PD. Previous data indicate
that the genetic alteration of GSK3B and its interaction
with MAPT haplotypes are collectively related to PD
morbidity rate in a Greek cohort [3,10]. However, the
association between the GSK3B gene alteration, MAPT
haplotype and PD has not been previously explored in
Chinese population.
In this study, our database contains 211 PD patients and
279 controls from central China. Our study examined the
possible association between GSK3B promoter single nu-
cleotide polymorphism (SNP) rs334558, MAPT haplotype,
MAPT intron SNP rs242562 and PD in central China.
Methods
Subjects
We recruited 211 unrelated sporadic PD patients (average
age at diagnosis: 57.23±12.9 years; 137 males, 74 females)
diagnosed according to the criteria of the UK Parkinson's
Disease Society Brain Bank in Union hospital, Tongji
Medical College, Huazhong University of Science and
Technology (TJMC & HUST). The control group con-
sisted of 279 individuals (average age: 53.72±13.32 years;
178 males, 101 females). This study was approved by the
Ethical Committee of TJMC & HUST. The ethics and
written informed consent was obtained from all subjects.
Genotyping
Genomic DNA was extracted from venous blood using
standard methods. Our primary objective was to select
MAPT polymorphisms previously suggested to contrib-
ute to the risk of developing idiopathic PD in Chinese
subjects. Therefore, we focused on the H1/H2 insertion/
deletion polymorphism and rs242562 [11]. PCR products
were generated with 50 ng DNA template in 12.5 μl1×t a q
PCR Master MIX (Bioteke Corporation, Beijing, China),
1 μlo f1 0μmol/l each primer (Invitrogen, Carlsbad, CA,
USA) and 12 μl Ultra-distilled water in a total volume of
25 μl. The PCR conditions used for the H1/H2 insertion/
deletion polymorphism were: the H1/H2 insertion/deletion
polymorphism forward primer GGAAGACGTTCTCACT
GATCTG, reverse primer AGGAGTCTGGCTTCAGTC
TCTC, initial denaturation at 94°C for 5 minutes followed
by 33 cycles of 94°C for 30 seconds, 59°C for 30 seconds,
72°C for 30 seconds, and a final extension at 72°C for
10 minutes. The PCR conditions used for the rs242562
polymorphism were: rs242562 forward primer: CAGCCT
TCCCTGTCCTTGATTC, rs242562 reverse primer; GCC
TTCCCAACAGAGCAACC, initial denaturation at 94°C
for 5 minutes, followed by 35 cycles of 94°C for 30 sec-
onds, 58°C for 30 seconds and 72°C for 30 seconds, and a
final extension at 72°C for 10 minutes. Digestion with
XhoI restriction enzyme (New England Biolabs, Ips-
wich, MA, USA) at 37°C yielded a 385 bp band for the
G-allele and a 287 bp and a 98 bp for the A-allele. The
PCR conditions used for the rs334558 polymorphism
were: rs334558 forward primer: GACGTCCGTGATT
GGCTC, reverse primer: AGCCCAGAGCCCTGTCAG,
initial denaturation at 94°C for 5 minutes, followed by
33 cycles of 94°C for 30 seconds, 62°C for 30s and
72°C for 15 seconds, with a final extension at 72°C for
10 minutes [12]. Digestion with AluI restriction enzyme
(New England Biolabs) at 37°C yields a 344 bp band for
the C allele and 220 and 124 bp for the T allele. Digestion
products were resolved on a 2% agarose gel, stained in
ethidium bromide solution and visualized with an ultra-
violet light.
Statistical analysis
All statistical analysis was performed by SAS 9.2 (SAS
Institute, Cary, NC). A log-odds ratio (OR) and its 95%
confidence interval (CI) were estimated with logistic
regression for allele wise, genotype-wise recessive/
dominant genetic model of each polymorphism. The
gene-gene interaction test was conducted by running
two models: one with and the other without the inter-
action term (A-carrier * T-carrier). In addition, a trend
test in logistic regression for allelic model was further
employed for the effect of MAPT rs242562 and GSK3B
rs334558 on risk for PD [13]. A probability (P)o fl e s st h a n
0.05 is considered statistically significant and P-values are
two-tailed. Adjustment of P values for multiple testing
uses Bonferroni correction. The power was calculated by
Power V3.0 software (http://dceg.cancer.gov/tools/design/
POWER) with the observed odds rates and minor allele
frequencies for both the 2-df overall association test and
the trend test [14].
Results
The allele and genotype distribution of MAPT rs242562
and GSK3B rs334558 in PD patients and controls were
summarized in Table 1. The schematic of the MAPT
region and associated polymorphisms including rs242562
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tions of rs242562 and rs334558 followed Hardy-Weinberg
equilibrium for PD patients and controls, no deviations
from equilibrium were observed. All the PD patients and
controls were of H1/H1 diplotype in our study.
For MAPT rs242562, we found positive results for
genotype-wise dominant genetic model in involved sub-
jects (Table 2, shown in bold) with a power of 74.5%.
Genotype AG+AA is associated with the higher PD risk
in overall involved subjects (AG+AA vs. GG, OR=1.785,
P =0.016), compared to genotype GG, with A as the
“putative” risk allele (Table 2). These data suggest that
AG+AA genotype of rs242562 may confer risk effect
on PD risk in central Chinese population. The ORs and
95% CIs for the case-control studies were not significant
for allele-wise model and the recessive model in overall
Table 1 Allele and Genotype frequencies of MAPT rs242562 and GSK3B rs334558 in PD cases and controls
Case(211) Control(279)
Number % Number % Number % Number % Number % Number %
rs242562
Allele A G A G
Total 230 55.02 188 44.98 225 48.91 235 51.09
Male 149 54.78 123 45.22 140 48.61 148 51.39
Female 81 55.48 65 44.52 85 49.42 87 50.58
Age< =50 80 54.05 68 45.95 102 43.97 130 56.03
Age> 50 150 55.56 120 44.44 123 53.95 105 46.05
Genotype AA AG GG AA AG GG
Total 57 27.27 116 55.5 36 17.22 59 25.65 107 46.52 64 27.83
Male 37 27.21 75 55.15 24 17.65 36 25 68 47.22 40 27.78
Female 20 27.4 41 56.16 12 16.44 23 26.74 39 45.35 24 27.91
Age< =50 20 27.23 40 54.05 14 18.92 27 23.28 48 41.38 41 35.34
Age> 50 37 27.41 76 56.3 22 16.3 32 28.07 59 51.75 23 20.18
rs334558
Allele C T C T
Total 260 61.61 162 38.39 330 62.98 194 37.02
Male 170 62.04 104 37.96 218 63.74 124 36.26
Female 90 60.81 58 39.19 112 61.54 70 38.46
Age< =50 97 65.54 51 34.46 163 65.73 85 34.27
Age> 50 163 59.49 111 40.51 167 60.51 109 39.49
Genotype CC CT TT CC CT TT
Total 74 35.07 112 53.08 25 11.85 97 37.02 136 51.91 29 11.07
Male 53 38.69 64 46.72 20 14.6 62 36.26 94 54.97 15 8.77
Female 21 28.38 48 64.86 5 6.76 35 38.46 42 46.15 14 15.38
Age< =50 27 36.49 43 58.11 4 5.41 52 41.94 59 47.58 13 10.48
Age> 50 47 34.31 69 50.36 21 15.33 45 32.61 77 55.8 16 11.59
Figure 1 Schematic of the MAPT region and associated polymorphisms. Previous studies have identified a ~970 kb inversion polymorphism
at chromosome 17q21.31, a region that contains MAPT and several other genes. Chromosomes with the inverted segment in different orientations
represent two highly divergent MAPT haplotypes, H1 (direct orientation) and H2 (inverted orientation). No recombination has been identified between
these two haplotypes over a region of ~1.5 Mb, but they have accumulated sequence variation independently. Polymorphisms including rs242562
and rs2435207 spanning MAPT exons 1 to 4 are specific to the H1 haplotype. Besides, there is a characteristic 238-bp deletion in the MAPT intron 9 of
the H2 haplotype.
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SNPs OR (95% CI) P Crude OR (95% CI) P Adjusted OR (95% CI)* P Crude OR (95% CI) P Adjusted OR (95% CI)* P
rs242562 (A/G) Allele-wise A vs. G AA vs. AG+GG AA vs. AG+ GG AG+ AA vs. GG AG+AA vs. GG
1.278 (0.980-1.666) 0.071 1.087 (0.711 – 1.662) 0.7 1.065 (0.693 – 1.636) 0.775 1.853 (1.169 – 2.936) 0.009 1.785 (1.116 – 2.853) 0.016
Power 0.266 0.058 0.048 0.793 0.745
rs334558 (T/C) Allele-wise T vs. C TT vs. CT+ CC TT vs. CT+ CC CT+ TT vs.CC CT+TT vs. CC
1.060 (0.814-1.381) 0.667 1.080 (0.612 – 1.907) 0.79 1.018 (0.573 – 1.808) 0.951 1.088 (0.746 – 1.588) 0.661 1.058 (0.719 – 1.557) 0.774
Power 0.05 0.044 0.029 0.064 0.064
* All the OR and P values were adjusted for age and gender.
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4involved subjects with a lower power of 0.048-0.266
(Table 2). Additionally, the test for trend in logistic
regression for allelic model also found no significant
association with a power of 0.143 (Table 3), which is
consistent with the results for allelic model in Table 2.
For GSK3B rs334558, the allele-wise and genotype-wise
ORs lack any statistical significance in overall involved sub-
jects with an insufficient power of 0.029-0.064 (Table 2).
The test for trend in logistic regression for allelic model
with a power of 0.036 (Table 3) also found null association
consistent with the allele-wise model in Table 2.
The gene-gene interaction test was conducted by run-
ning two models: with and without the interaction term
(A-carrier * T-carrier), and likelihood ratio test indicated
that interaction term was not statistically significant
(P = 0.2140). The effect of GG and age on PD risk
remained the same between the two models. We then
studied the association between rs242562 and PD at
different levels of the rs334558 genotype (Additional
file 1: Table S1), and the association between rs334558
and PD at different levels of the rs242562 genotype
(Additional file 2: Table S2). The results suggest that
the GG genotype of rs242562 displays protection against
PD in subgroup with Tcarrier, although the stratified ana-
lysis has a smaller sample size and a lower statistic power.
Discussion
In this study, we investigated the association of MAPT
rs242562 and GSK3B rs334558 with PD in central China.
The main findings of our study in central Chinese popula-
tion include 1) All the PD patients and controls were in
H1/H1 diplotype in our study, 2) GG genotype of MAPT
rs242562 serves protection effect on PD risk in central
Chinese population, 3) Genotype of GSK3B rs334558
showed no difference between PD patients and controls,
and 4) GG genotype of rs242562 may display strong pro-
tective effect against PD risk in subgroup with GSK3B
rs334558 Tcarrier.
Our data confirmed that the distribution of the MAPT
H1 haplotype is common in China, which is in agreement
with previous findings [15,16]. Accumulating evidence
showed that MAPT H1 haplotype-carrier group is a
susceptible group of PD [16,17]. This case-control study
served as an association study based on population
with susceptible haplotype H1 in central China. MAPT
rs242562 regulates protein encoding despite it is in
the intron of MAPT gene. The frequency of rs242562
GG genotype is higher in controls compared to that in
cases, indicating it may play a protective role. These data
are different from a previous study which showed that
MAPT polymorphism rs242562 revealed no significant
difference between PD patients and controls in Germany,
Serbia and Greece [6,18,19]. The sample size, ethnic groups
and environment may contribute to the different results.
GSK3B rs334558 is reportedly associated with PD, but
the conclusions were inconsistent. A Greek study was
the first to show that GSK3B rs334558 was related to
PD, while CC served a protective effect and TT was
overexpressed in PD [18]. Moreover, a study from
Australia showed that the frequency of TT and H1/H1
diplotype in PD patients was significantly higher com-
pared to control subjects [10]. However, the study about
LOPD patients in India concluded that CC was a risk
factor [20]. In the Spanish population, TT genotype and
MAPT H1/H1 diplotype were associated with a de-
creased risk for PD [21]. In the present study, we did
not find any significant difference in allele-wise and
genotype-wise analysis for rs334558 between PD patients
and controls. However, GG genotype of rs242562 may
serve a strong protective effect on PD risk in subgroup
with T carrier, although the stratified analysis has a small
sample size and a low statistic power.
Sex may be involved in the association results of GSK3B
and neurodegenerative disease [22]. In an Alzheimer's
disease research, it was revealed that estrogen receptor
and GSK3B could change the tau protein phosphorylation,
Table 3 The allelic-wise analysis with a test for trend for the effect of MAPT rs242562 and GSK3B rs334558 on risk for PD
Number of minor alleles Cases Controls Crude OR (95% CI) P value Adjusted OR (95% CI)* P* value
rs242562
0 36 64 1.000 1.000
1 116 107 1.927(1.186,3.132) 0.008 1.892(1.154,3.102) 0.011
2 56 60 1.659(0.960,2.868) 0.070 1.628(0.931,2.846) 0.087
Test for trend 1.262(0.964,1.651) 0.091 1.250(0.950,1.646) 0.111
rs334558
0 74 97 1.000 1.000
1 112 136 1.079(0.729,1.598) 0.702 1.051(0.704,1.570) 0.807
2 25 29 1.130(0.611,2.089) 0.697 1.091(0.583,2.039) 0.785
Test for trend 1.068(0.806,1.415) 0.647 1.047(0.785,1.395) 0.756
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generative disease [22]. However, following sex stratifi-
cation the sample size was smaller in our study, and
whether hormonal or hormonal receptors change the
association of GSK3B gene with PD needs to be further
investigated.
Although MAPT rs242562 and GSK3B rs334558 are
located in two different chromosomes, the encoded pro-
teins interact with each other. Given the findings that
H1 haplotype may act synergistically with variants in the
MAPT and GSK3B genes in conferring risk for PD,
gene-gene interactions will also be important to consider
as they may provide critical insights into mechanisms
of disease susceptibility. In this study, lower power was
observed for rs334558 analysis. Thus, the null association
should attribute to the insufficient power. Since the
sample size of the genotype model including indicator
variables of the two polymorphisms is considerably
smaller, a larger sample size should be needed in order
to further assess this association.
Conclusions
In summary, the MAPT rs242562 is associated with PD in
central China, and GG genotype of rs242562 may provide
protective effect against PD risk in subgroup with GSK3B
rs334558 T carrier, although our results are limited by
the sample size. Since MAPT gene and GSK3B gene
confer genetic risk for PD, exploring how the gene-gene
or gene-environment interactions contribute to dopamin-
ergic neurodegeneration should be further considered.
Such knowledge about the mechanisms could open up
new windows for early diagnostic and therapeutic inter-
ventions in this important neurodegenerative disease.
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